مجله علمی پژوهشی سازمان نظام پزشکی
Volume 37, Issue 3 (2020)                   jmciri 2020, 37(3): 131-138 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Management of Hepatic Cholestasis. jmciri 2020; 37 (3) :131-138
URL: http://jmciri.ir/article-1-2927-en.html
Abstract:   (10131 Views)
Hepatic cholestasis is characterized by elevated alkaline phosphatase and gama - glutamyl transpeptidase levels which is then followed by conjugated hyperbilirubinemia. It is classified into intrahepatic and extrahepatic cholestasis.
Intrahepatic cholestasis indicates hepatocellular dysfunction or the presence of an obstructive lesion in intrahepatic bile ducts distal to biliary canalicular system.
The first step in evaluating cholestasis is to distinguish intrahepatic from extrahepatic cholestasis. Abdominal sonography is a sensitive and specific modality to rule out intra- and extrahepatic biliary dilatation. If abnormal biliary tract is present, the next step is to perform Magnetic Resonance Cholangiopancreatography (MRCP) or Endoscopic Ultrasound (EUS). If there was not any evidence of biliary system obstruction in imaging, intrahepatic cholestasis is suggested and to evaluate this condition, initially Antimitochondrial antibody (AMA) should be checked and if the result was negative, liver biopsy should be considered.
Full-Text [PDF 935 kb]   (15033 Downloads)    
Type of Study: Research | Subject: General

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.